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ABSTRACT
The Republic of Belarus reports a seroprevalence of 4.8% for hepatitis B virus (HBV) and 1.26% for
hepatitis C virus (HCV), but little is known about the molecular characteristics of the circulating viruses.
This study analysed 69 HBV surface antigen (HBsAg)-positive and 113 anti-HCV-positive donors
attending a national reference hospital in Minsk. Among the HCV patients, 70% were co-infected with
human immunodeficiency virus (HIV). Phylogenetic analysis of 12 complete genomes and 31 partial
HBV sequences, as well as 78 core ⁄E1 HCV sequences, revealed that multiple genotypes and subtypes of
both viruses were circulating in Belarus. Of the HBV strains, 11.6% were genotype A2 and 88.6% were
genotype D. The genotype D strains segregated into four recently described subtypes, with D2 being the
most prevalent (58.1%), followed by D3 (16.3%), D1 (11.6%) and D4 (2.3%), but with inter-subtypic
distances lower than the minimal 4% distance proposed to define subtypes. The 78 HCV strains
belonged to subtypes 1b (53.8%), 3a (38.5%), 1a (5.1%), 4a (1.3%) and 4d (1.3%). Subtype 1b was less
prevalent (45.1% vs. 70.4%) among HCV ⁄HIV co-infected donors, while subtype 3a was more prevalent
(29.6% vs. 43.1%). The relative prevalence of HBV and HCV genotypes in Belarus corresponded to the
prevalence in Russia, although with a clear European influence that reflected the socio-political context
of the country.
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INTRODUCTION
With an estimated 387 million individuals world-
wide who are chronically infected with hepati-
tis B virus (HBV), and a further 170 million who
are infected with hepatitis C virus (HCV) [1,2],
these infections pose major public health prob-
lems. There is increasing evidence that the risk of
developing severe liver disease, and the varying
response to antiviral treatment, is influenced by
the virus genotypes and subtypes involved [3–5].
HBV has been classified phylogenetically into
eight genotypes (A–H) with different geographi-
cal distributions [6,7]: genotype A is predominant
in western Europe, North America, and South
and East Africa [8,9]; genotypes B and C are
prevalent in Asia [7,10]; genotype D has a world-
wide distribution, with its highest prevalence in
the Mediterranean region [8]; genotype E is found
throughout sub-Saharan Africa [11–13]; geno-
type F is found in South and Central America
[14]; genotype G is found in France, Georgia, the
USA [15] and Germany [16]; and genotype H is
found in the Amerindian populations of Central
America [17].
HCV has at least six major genotypes (1–6),
with more than 60 subtypes [18–20]. HCV sub-
types 1a, 1b, 2a, 2b, 2c and 3a are responsible for
>90% of infections in North and South America,
Europe and Japan. In the USA, subtypes 1a and
1b each account for c. 35% of infections [21],
while 73% are caused by subtype 1b in Japan [22].
Subtype 3a is predominant among intravenous
drug users in Europe and the USA [23], geno-
type 4 is prevalent in North Africa and the
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Middle East [24,25], and genotypes 5 and 6 are
found in South Africa and Hong Kong, respec-
tively [26,27].
Data concerning the genotype distribution of
HBV and HCV are very limited for certain parts
of the world, especially developing countries and
some of the Republics of the former Soviet Union.
The Republic of Belarus reports a seroprevalence
of 4.8% for HBV and 1.26% for HCV, but little is
known concerning the molecular characteristics of
the circulating viruses. Accordingly, the present
study investigated the molecular characteristics of
HBV and HCV strains from Belarus.
MATERIALS AND METHODS
Clinical samples
In total, 157 serum samples were obtained during 2004–2005
from patients of known hepatitis B surface antigen (HBsAg)
and anti-HCV status who were attending the Infectious
Disease Hospital, Minsk, Belarus. The residents of Minsk
account for c. 25% of the country’s population and are repre-
sentative of the entire population. The Infectious Disease
Hospital is the largest hospital in Belarus, and acts as a central
referral hospital for patients from throughout the country. HBV
and HCV were confirmed using the Murex HBsAg kit v.3
(Abbott Diagnostics, Louvain-la-Neuve, Belgium) and the
Ortho HCV 3.0 ELISA system (Ortho-Diagnostics, Beerse,
Belgium). HBV DNA and HCV RNAwere detected by RT-PCR
and ⁄ or PCR (Table 1). Co-infection with human immunodefi-
ciency virus (HIV) was diagnosed in 51% of all donors,
including 8.7% of HBsAg carriers and 69.9% of anti-HCV-
positive donors; 64.6% of the latter were positive forHCVRNA.
Amplification and cloning
Nucleic acid extraction and complete HBV genome amplifica-
tion were performed as described previously [13]. For ampli-
fication of the core ⁄E1 region of HCV, a semi-nested PCR was
performed in a 25-lL reaction containing 0.5 lL cDNA,
2.5 mM MgCl2, 200 nM dNTPs, 50 nM each primer
(fw290utr(+), 5¢-TGCCTGATAGGGTGCTTGCGAG, pos.
290–311; 1321e1()), 5¢-ACCAGTTCATCATCATATCCCATG
CCAT, pos. 1293–1320), and 1 U Platinum Taq DNA
polymerase with 1 · PCR buffer. PCRs comprised 95C for
5 min, followed by 40 cycles of 95C for 1 min, 63C for 1 min
and 72C for 1 min. Nested PCRs were performed using the
same conditions with 5 lL of the first-round product diluted
1:100, but with a different forward primer (fw480c(+),
5¢-CGCGCGACTAGGAAGACTTC, pos. 480–499; rv1321e1),
0.10 lM each primer, 2 lM MgCl2 and an annealing temper-
ature of 62C. The product of the first round S fragment PCR
was cloned using the pCR4-TOPO kit (Invitrogen, Hilden,
Germany) according to the manufacturer’s protocol.
Sequencing and phylogenetic analysis
The nested and M13 PCR products were purified and
sequenced as described previously [13]. Phylogenetic analysis
was performed using MEGA4 [28] with the neighbour-joining
and Kimura two-parameter method. HCV sequences included
the core to E1 region with a total length of c. 844 bp (pos. 480–
1323, according to HCV H77). For each HBV strain, phyloge-
netic analysis was performed for the combined preS and S
fragment sequences (pos. 56–2423, according to X75664), as
well as the full-length genome, if available. All sequences were




Overall, 44 (28%) patients were positive for
HBsAg only, 88 (56%) were positive for anti-
HCV antibodies only, and 25 (15.9%) were
positive for both serological markers. For HBV,
<10% were HIV-positive. Similar values have
been reported in other countries [29]. Thirty-seven
(84.1%) of the 44 HBsAg-positive samples, one
(1.2%) of 88 anti-HCV-positive samples and five
(20%) of 25 double-positive samples (20%) were
positive according to at least one of the four nested
PCRs covering the preS, S, X and C genes of HBV
(Table 1) and were adequate for genotyping. One
patient was HBsAg-negative but HBV DNA-
positive. Complete genomic sequences were
obtained for 12 strains. Phylogenetic analysis,
based on the preS or the complete genome
sequences, revealed that 38 (88.4%) patients were
infected by genotype D and five (11.6%) by
subtype A2. Despite the co-circulation of multi-
ple genotypes in Belarus, cloning experiments
revealed no evidence of mixed infections or
recombinations. Subtypes of genotype D have
been recognised only recently in phylogenetic
studies [1]. The strains from Belarus segregated
into four subtypes (Table 2): D1 (n = 5), D2
(n = 25), D3 (n = 7) and D4 (n = 1) (Fig. 1). There
Table 1. Comparison of PCR results with the results of
ELISAs for hepatitis B surface antigen (HBsAg) and anti-





Positive 42 (26.7%) 27 (17.2%) 69 (43.9%)
Negative 1 (0.6%) 87 (52.2%) 88 (56.1%)




Positive 78 (49.7%) 35 (22.3%) 113 (72%)
Negative 0 44 (28%) 44 (28%)
Total 78 (49.7%) 79 (50.3%) 157
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was no significant difference in genotype or
subtype distribution between HIV-positive and
HIV-negative patients. Three complete genome
sequences were obtained for each of the identified
subtypes except D4, for which the fragments from
nucleotides 198–2418 were missing.
Analysis of sequences available from Gen-
bank ⁄DDBJ ⁄EMBL revealed that countries north
(Estonia, Latvia) [30] and south (Hungary, Serbia)
[31,32] of Belarus had a similar distribution of
genotypes A and D, with the prevalence of
genotype D ranging from 71% to 82%, and
that of genotype A ranging from 18% to 28%.
In Estonia, Latvia and Hungary, subtype D2 was
the most prevalent (50.8–66.6%), followed by
subtypes D3 and D1. Further south in Serbia,
subtype D3 was dominant (43.2%), followed by
subtype D2 (32.9%). To the west of Belarus, e.g.,
in Poland [33] and the Czech Republic [34],
genotype A becomes dominant over genotype D
(86.5% vs. 13.5%, and 73% vs. 27%, respectively).
No sequence data were available from the latter
countries. In contrast, genotype D is predominant
in Russia [35], accounting for >90% of isolates,
consisting mainly of subtype D2 (80.6%), fol-
lowed by subtype D3 (12.9%) and subtype D1
(3.2%). Thus, as in the Baltic States, the genotype
distribution found in Belarus resembles that
found in Russia, although not without clear
influences from western Europe. No HBV geno-
type data were available for Lithuania, Romania,
Ukraine and Bulgaria.
Since genotype D subtypes have, to date, been
described only rarely [1,36,37], the Belorussian
strains were considered in the context of the
proposed criteria for the definition of new
subtypes. Sequence analysis of complete ge-
nomes revealed an average intra-subtypic genet-
ic distance of 1.5% within the genotype D
subtypes (subtype D4 excluded), while the max-
imal inter-subtypic genetic distance (subtype D4
excluded) was 2.9%, with subtype D3 being the
most divergent from the other two subtypes
(2.7% from subtype D1 and 2.9% from
subtype D2). The average distance between sub-
types D1 and D2 was 2.2% (Table 3). The inter-
subtypic distances of all available strains were
actually lower than the minimal 4% distance
proposed to define subtypes [1], but phyloge-
netic reconstructions nevertheless allowed an
unambiguous separation, with bootstrap values
of 100% at the nodes separating the different
subtypes on the phylogenetic tree calculated
using complete genome sequences (Fig. 1b).
Subtypes D1 and D2 are phylogenetically close
and are thought to have evolved in Europe and
western Russia [1]. Subtype D3 probably origi-
nated in Russia and spread to Japan [1,38].
Subtype D4 is found predominantly in Australia
and Papua New Guinea, and is also the subtype
that is genetically most distant from the
other genotype D subtypes. BLAST searches of
complete genomes revealed that the closest
relatives with known origins were: subtype D1,
AB222711 from Uzbekistan; subtype D2, Z35716
from Poland; subtype D3, DQ111987 from Mon-
golia; and subtype A2, AB116079 from Japan.
A BLAST search, based on the S gene of
subtype D4, returned AB033559 from Papua
New Guinea.
Table 2. Genotype distribution of hepatitis B virus (HBV) and hepatitis C virus (HCV) strains in Belarus
HBV genotype
Patients D1 D2 D3 D4 A2 Total
HBsAg+ 43 4 (11.1%) 21 (58.3%) 6 (16.7%) 1 (2.8%) 4 (11.1%) 36
HBsAg ⁄ anti-HCV+ 20 0 1 (100%) 0 0 0 1
HBsAg ⁄HIV+ 1 0 1 (100%) 0 0 0 1
HBsAg ⁄ anti-HCV ⁄HIV+ 5 1 (25%) 2 (50%) 0 0 1 (25%) 4
Anti-HCV+ ⁄HIV+ and ) 88 0 0 1 (100%) 0 0 1
Total 157 5 (11.6%) 25 (58.1%) 7 (16.28%) 1 (2.3%) 5 (11.6%) 43
HCV genotype
Patients 1a 1b 3a 4a 4d Total
Anti-HCV+ 14 0 9 (81.8%) 2 (18.2%) 0 0 11
Anti-HCV ⁄HBsAg+ 20 0 10 (62.5%) 6 (37.5%) 0 0 16
Anti-HCV ⁄HIV+ 74 4 (8.1%) 21 (42.9%) 22 (44.9%) 1 (2.0%) 1 (2.0%) 49
Anti-HCV ⁄HBsAg ⁄HIV+ 5 0 2 (100%) 0 0 0 2
HBsAg+ ⁄HIV+ and ) 44 0 0 0 0 0 0
Total 157 4 (5.1%) 42 (53.8%) 30 (38.5%) 1 (1.3%) 1 (1.3%) 78
HBsAg, HBV surface antigen; anti-HCV, anti-HCV antibody; HIV, human immunodeficiency virus.
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HCV
Almost 70% of HCV patients were co-infected
with HIV, which is similar to the percentages
reported in other countries [39]. In 60 of the 88
patients who were positive only for anti-HCV,
and in 18 of the 25 patients who were positive for
HBsAg and anti-HCV (Table 2), HCV RNA was
detected and sequenced in the core ⁄E1 region
(Tables 1 and 2). Phylogenetically, the 78 strains
belonged to HCV subtypes 1b (53.8%), 3a
(38.5%), 1a (5.1%), 4a (1.3%) and 4d (1.3%)
(Table 2; Fig. 2). A previous study in 1997 [40]
reported that subtype 1b was the most prevalent
subtype (76%), followed by subtype 3a (19%) and
single cases of subtypes 1a and 2a, which sug-
(a)
(b)
Fig. 1. Phylogenetic reconstruction of (a) the preS frag-
ment, and (b) the complete genome of representative
examples of the hepatitis B virus strains found in Belarus
(indicated by ) and reference sequences. Bootstrap values
of relevant nodes are indicated. Trees have been calculated
using the neighbour-joining method and the Kimura two-
parameter model.
Table 3. Distances (%) within (shown in bold) and among
the different genotypes and subtypes of hepatitis B virus
present in Belarus
preS A2 D1 D2 D3 D4
A2 0.9 (1.04)
D1 10.5 (17.52) 1.3 (1.41)
D2 10.6 (17.52) 2.2 (2.78) 1.7 (1.98)
D3 10.5 (17.73) 2.7 (3.18) 2.9 (3.75) 1.5 (1.48)
D4 NA (17.68) NA (5.09) NA (5.77) NA (5.14) NA (NA)
aCalculations are based on complete genome or preS fragment (number in
parentheses) sequences. NA, not applicable.
Fig. 2. Phylogenetic reconstruction of the core ⁄E1 region
of representative examples of the hepatitis C virus strains
found in Belarus (indicated by ) and reference sequences.
Bootstrap values of relevant nodes are indicated. Trees
have been calculated using the neighbour-joining method
and the Kimura two-parameter model.
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gests that the prevalence of subtype 3a has
increased and that fewer subtype 1b strains are
now circulating. Subtypes 1b and 3a are also
dominant over other subtypes in Russia, Estonia
and western Europe [41]. While both subtypes
have a similar prevalence (45%) in Russia, the
relative prevalence of subtype 1b over subtype 3a
is three-fold greater in Estonia (71% vs. 24%; [30])
and 6.5-fold higher in western Europe (58% vs.
9%). In Russia and Estonia, the prevalence of all
other subtypes is <2% and <1%, respectively,
while subtype 1a accounts for 20% of strains in
Europe. Thus, with a 1.5-fold dominance of
subtype 1b over subtype 3a, and a prevalence of
5.1%, the subtype pattern of HCV in Belarus is
similar to that in Russia, although not without a
clear western European influence. Subtypes 1a, 4a
and 4d were found only in HIV-positive patients,
while the prevalences of subtypes 1b and 3a were
70.4% and 29.6%, respectively, in HIV-negative
patients, and 45.1% and 43.1%, respectively, in
HIV-positive patients (Table 2). Similar studies,
e.g., in Spain [42], have also revealed that sub-
types 1a and 3a are more prevalent among HIV-
positive donors, indicating that separate trans-
mission networks exist for different HCV
subtypes, e.g., among intravenous drug users
[43].
In the HCV strains found in Belarus, the
average distances at the nucleotide level were
5.7–7.1% within subtypes, and 22.4–33.8% among
subtypes, with an average distance among all
Belorussian strains of 21.8%. The diversity within
subtype 3a in Belarus was 1.7-fold less than the
diversity of all worldwide strains belonging to the
same subtype, while for subtype 1b it was 1.2-fold
less. Despite the higher prevalence of subtype 1b,
this may indicate that subtype 3a has been circu-
lating longer in Belarus, or that it has been
introduced on multiple occasions from various
sources and ⁄ or countries. BLAST searches of the
different HCV strains did not reveal a closer
relationship of Belorussian subtypes with other
strains from the same geographical region, but
indicated similarities for both subtypes 1b and 3a
with strains found worldwide. For subtype 1b,
this could be explained by the worldwide use of
contaminated blood products, e.g., in anti-
D immunoglobulin in 1977 [44]. However, for
subtype 3a, circumstances similar to those in
Egypt may have caused its spread [45]. At the
protein level, the HCV strains did not reveal any
amino-acid substitutions that were specific to
strains or subtypes found in Belarus, thereby
confirming that multiple introductions from
abroad had probably occurred.
In conclusion, HBV genotype D strains in
Belarus form phylogenetic clusters (D1–D4) that
are compatible with the four subtypes proposed
recently, although the inter-subtypic distances
may be lower than required. The relative preva-
lence of genotypes of both HBV and HCV in
Belarus reflect the frequencies found in Russia,
although with clear European influences, possibly
explained by the socio-political context of the
country. Surprisingly, the virus variants do not
seem to be related to those from neighbouring
countries.
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